DÄ internationalArchive21/2007Disorders of Blood Clotting


Disorders of Blood Clotting

Dtsch Arztebl 2007; 104(21): A-1489

Luxembourg, B; Krause, M; Lindhoff-Last, E

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

1. McFarlane RG: An enzyme cascade in the blood clotting mechanism and its function as a biological amplifier. Nature 1964; 202: 498–9.
2. Spannagl M, Moessmer G: Hämostaseologische Globalteste. Hämostaseologie 2006; 1: 27–37. MEDLINE
3. Barthels M, von Depka M: Das Gerinnungskompendium. Stuttgart: Thieme Verlag 2003.
4. Pötzsch B, Madlener K: Gerinnungskonsil. Rationelle Diagnostik und Therapie von Gerinnungsstörungen. Stuttgart: Thieme Verlag 2002.
5. Koscielny J, Ziemer S, Radtke H et al.: A practical concept for preoperative identification of patients with impaired primary hemostasis. Clin Appl Thromb Hemost 2004; 10: 195–204. MEDLINE
6. Lillicrap D, Nair SC, Srivastava A, Rodeghiero F, Pabinger I, Federici AB: Laboratory issues in bleeding disorders. Haemophilia 2006; 12 (Suppl 3): 68–75. MEDLINE
7. Peyvandi F, Kaufman RJ, Seligsohn U et al.: Rare bleeding disorders. Haemophilia 2006; 12 (Suppl 3): 137–42. MEDLINE
8. Koscielny J, Radtke H, Ziemer S, Pindur G, Jung F, Kiesewetter H, Wenzel E: Normalisierung der Thrombozytenfunktion durch Desmopressin. Präoperativer Einsatz bei durch Acetylsalicylsäure (ASS) und nichtsteroidale Analgetika induzierter Thrombozytopathie. Anästhesie und Intensivmedizin (A-naesth Intens Care) 1995; 36: 205–10.
9. Jackson CM, White GC: Scientific and standardization committee communication: a reference system approach to future standardization of laboratory tests for hemostasis. Posted on ISTH Website 2001. http://www.med.unc.edu/isth/
10. Fressinaud E, Vayradier A, Truchaud F et al.: Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood 1998; 9: 1325–31. MEDLINE
11. Favaloro EJ: The utility of the PFA-100 in the identification of von Willebrand disease: a concise review. Semin Thromb Hemost 2006; 32: 537–45. MEDLINE
12. Mani H, Linnemann B, Luxembourg B, Kirchmayr K, Lindhoff-Last E: Response to aspirin and clopidogrel monitored with different platelet function methods. Platelets 2006;17: 303–10.
13. Reininger AJ: Primary haemostasis and its assessment by laboratory tests. Hämostaseologie 2006; 1: 42–7. MEDLINE
14. Hayward CPM, Harrison P, Cattaneo M, Ortel TL, Rao AK: Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006; 4: 312–9. MEDLINE
15. Fattorutto M, Pradier O, Schmartz D, Ickx B, Barvais L: Does the platelet function analyser (PFA-100®) predict blood loss after cardiopulmonary bypass? Br J Anaesth 2003; 90: 692–3. MEDLINE
16. Wahba A, Sander S, Birnbaum DE: Are in-vitro platelet function tests useful in predicting blood loss following open heart surgery? Thorac Cardiovasc Surg 1998; 46: 228–31. MEDLINE
17. Cammerer U, Dietrich W, Rampf T, Braun SL, Richter JA: The predictive value of modified computerized thromboelastography and platelet function analysis for postoperative blood loss in routine cardiac surgery. Anesth Analg 2003; 96: 51–7. MEDLINE
18. Topol EJ, Gum P, Kottke-Marchant K: Determination of the natural history of aspirin resistance among stable patients with cardiovascular disease: Reply. J Am Coll Cardiol 2003; 42: 1336–7. MEDLINE
19. Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T: A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232: 155–60. MEDLINE
20. Bertina RM, Koeleman BP, Koster T et al.: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64–7. MEDLINE
21. Heeb MJ, Kojima Y, Greengard JS, Griffin JH: Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V. Blood 1995; 85: 3405–11. MEDLINE
22. Aparicio C, Dahlbäck B: Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene. Biochem J 1996; 313: 467–72. MEDLINE
23. Dahlbäck B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004–8. MEDLINE
24. Schroder W, Koesling M, Wulff K, Wehnert M, Herrmann FH: Large-scale screening for factor V Leiden mutation in a north-eastern German population. Haemostasis 1996; 26: 233–6. MEDLINE
25. Griffin JH, Evatt BL, Wideman C, Fernandez JA: Anticoagulant protein C pathway defective in a majority of thrombophilic patients. Blood 1993; 82: 1989–93.
e1. Hainaut P, Azerad MA, Lehmann E et al.: Prevalence of activated protein C resistance and analysis of clinical profile in thromboembolic patients. A Belgian prospective study. J Intern Med 1997; 241: 427–33. MEDLINE
e2. Melichart M, Kyrle PA, Eichinger S, Rintelen C, Mannhalter C, Pabinger I: Thrombotic tendency in 75 symptomatic, unrelated patients with APC resistance. Wien Klin Wochenschr 1996; 108: 607–10. MEDLINE
e3. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP: Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912–17. MEDLINE
e4. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH: High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504–8. MEDLINE
e5. Gehring NH, Frede U, Neu-Yilik G et al.: Increased efficiency of mRNA 3`end formation: a new genetic mechanism contributing to hereditary thrombophilia. Nat Genet 2001; 28: 389–92. MEDLINE
e6. Ceelie H, Spaargaren-van Riel CC, Bertina RM, Vos HL: G20210A is a functional mutation in the prothrombin gene; effect on protein levels and 3`-end formation. J Thromb Haemost 2004; 2: 119–27. MEDLINE
e7. Pollak ES, Lam HS, Russell JE: The G20210A mutation does not affect the stability of prothrombin mRNA in vivo. Blood 2002; 100: 359–62. MEDLINE
e8. Rosendaal FR, Doggen CJ, Zivelin A et al.: Geographic distrubition of the 20210 G to A prothrombin variant. Thromb Haemost 1998; 79: 706–8. MEDLINE
e9. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM: A common genetic variation in the 3`untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698–703. MEDLINE
e10. Arruda VR, Annichino-Bizzacchi JM, Gonclaves MS, Costa FF: Prevalence of the prothrombin gene variant (nt20210) in venous thrombosis and arterial disease. Thromb Haemost 1997; 78: 1430–3. MEDLINE
e11. Conley CL, Hartmann RC: A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 1952; 31: 621–2.
e12. Asherson RA: Antiphospholipid antibodies, malignancies and paraproteinemias. J Autoimmunity 2000; 15: 117–22. MEDLINE
e13. Vaarala O, Palosuo T, Kleemola M, Aho K: Anticardiolipin response in acute infection. Clin Immunol Immunopathol 1986; 41: 8–15. MEDLINE
e14. Frauenknecht K, Lackner K, von Landenberg P: Antiphospholipid antibodies in pediatric patients with prolonged activated partial thromboplastin time during infection. Immunbiology 2005; 210: 799–805. MEDLINE
e15. Miyakis S, Lockshin MD, Atsumi T et al.: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306. MEDLINE
e16. Brandt JT, Triplett DA, Alving B, Scharrer I: Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995; 74: 1185–90. MEDLINE
e17. Greaves M, Cohen H, Machin SI, Mackie I: Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000; 109: 704–15. MEDLINE
e18. Simioni P, Prandoni P, Zanon E et al.: Deep venous thrombosis and lupus anticoagulant – A case control study. Thromb Haemost 1996; 76: 187–9. MEDLINE
e19. Mateo J, Oliver A, Borrell M et al.: Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism – Results of the Spanish multicentric study on thrombophilia (EMET-study). Thromb Haemost 1997; 77: 444–51. MEDLINE
e20. Ginsberg JS, Wells PS, Brill-Edwards P et al.: Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685–91. MEDLINE
e21. Kamashta MA, Cudtrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV: The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993–7. MEDLINE